Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood pH

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    607 result(s) found for: Blood pH. Displaying page 8 of 31.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2006-000881-35 Sponsor Protocol Number: CLBH589B2202 Start Date*: 2007-01-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors
    Medical condition: Adult patients with chronic phase Ph+ CML whose disease is resistant following treatment with at least two BCR-ABL tyrosine kinase inhibitors (i.e. imitinib, nilotinib, or dasatinib).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009015 Chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) NL (Completed) FR (Completed) GB (Prematurely Ended) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002203-15 Sponsor Protocol Number: PregMet2 Start Date*: 2012-08-08
    Sponsor Name:NTNU, Norwegian University of Science and Technology
    Full Title: Metformin treatment of pregnant PCOS women and prevention of late miscarriages and preterm birth The PregMet 2 Study
    Medical condition: Poly Cystic Ovarial Syndrome (PCOS) in pregnant women. PCOS should be diagnosed according to the Rotterdam Consensus criterias: - at least 2 out of 3 criterias 1.PCO in at least one ovary 2.Olig...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed) SE (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2004-003836-77 Sponsor Protocol Number: OCTO-003 Start Date*: 2008-12-09
    Sponsor Name:University of Oxford
    Full Title: AspECT - A phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia & oesophagitis.
    Medical condition: Barrett's Metaplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005513-18 Sponsor Protocol Number: FARM6NJ3TZ Start Date*: 2007-10-04
    Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA
    Full Title: Double blind randomized controlled study on the benefit-risk profile of in the treatment of at term or late preterm newborn infants with severe respiratory disorders and pulmonary hypertension
    Medical condition: treatment of at term or late preterm newborn infants with severe respiratory disorders and pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    10037400 PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005681-13 Sponsor Protocol Number: CLCI699A2206 Start Date*: 2008-03-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A pilot, single-blind, forced-titration study to assess the hemodynamic and hormonal effects, safety and tolerability of the aldosterone synthase inhibitor LCI699 in patients with primary hyperaldo...
    Medical condition: hypertension artérielle par hyperaldostéronisme primaire
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039834 Secondary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002059-40 Sponsor Protocol Number: ECT-LANS-IL2 Start Date*: 2012-06-28
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Potentiating clinical and immunological effects of chemotherapy by neutralizing acidic pH at tumor site: a phase II randomized study in melanoma patients
    Medical condition: Metastatic Cutaneous and Subcutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000383-18 Sponsor Protocol Number: LAL1913 Start Date*: 2014-05-20
    Sponsor Name:G.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto
    Full Title: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented...
    Medical condition: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003517-17 Sponsor Protocol Number: ALL2518 Start Date*: 2019-09-26
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Asparaginase Activity Monitoring (AAM) in adult patients with Acute Lymphoblastic Leukemia (ALL).
    Medical condition: Adult patients, aged between 18 and 65, diagnosed with Acute Ph Lymphoblastic Leukemia negative (LAL Ph-) untreated, with a favorable impact on the prognosis.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060390 Leukaemia lymphoblastic acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006441-10 Sponsor Protocol Number: 116-02 Start Date*: 2009-06-03
    Sponsor Name:SCIPHARM SáRL
    Full Title: A double blind controlled clinical study to investigate the efficacy and tolerability of subcutaneous Treprostinil sodium in patients with severe non-operable Chronic Thromboembolic Pulmonary Hyper...
    Medical condition: Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) SK (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003423-21 Sponsor Protocol Number: IK-7002-COPD-006 Start Date*: 2014-09-29
    Sponsor Name:Bellerophon Pulse Technologies LLC
    Full Title: An Exploratory, Two-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects with World Health Organization (WHO) Group...
    Medical condition: Part 1: Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) Part 2: Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017594-37 Sponsor Protocol Number: CVAL489K2305 Start Date*: 2011-06-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, open-label 18 month study to evaluate the long-term safety and tolerability of valsartan in children 6 to 17 years of age with hypertension and with or without chronic kidney disease.
    Medical condition: Hypertension.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004119-30 Sponsor Protocol Number: IP-AVV2019 Start Date*: 2020-01-08
    Sponsor Name:Instituto Palacios
    Full Title: EVALUATION OF THE ACCEPTABILITY AND EFFICACY OF 10 MICROGRAMS OF ESTRADIOL VAGINAL TABLETS VS PROMESTRIENE VAGINAL CREAM
    Medical condition: VULVOVAGINAL ATROPHY
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001005-41 Sponsor Protocol Number: fluresstudy Start Date*: 2014-12-10
    Sponsor Name:Ghent University Hospital
    Full Title: Evaluation of FLuid REsuscitation with Sterofundin ® ISO (Ringerfundin), Plasma-Lyte® or NaCl 0.9%. (FluReS study)
    Medical condition: hypovolemia-->need for fluid therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003912-28 Sponsor Protocol Number: ALL2620 Start Date*: 2021-01-28
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Ponatinib for the management of minimal residual disease (MRD) and hematologic relapse in adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients.
    Medical condition: Ph+ Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004854-33 Sponsor Protocol Number: 03-AnIt-14/UKM14_0066 Start Date*: 2016-02-05
    Sponsor Name:University Hospital Muenster
    Full Title: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH-Trial).
    Medical condition: Critically ill patients with acute kidney injury
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004823-11 Sponsor Protocol Number: remifentanil2011 Start Date*: 2012-08-03
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
    Full Title: Randomized prospective multicenter study on remifentanil analgesic efficacy in labor: intermittent intravenous infusion administration vs continuous intravenous infusion
    Medical condition: women during labor
    Disease: Version SOC Term Classification Code Term Level
    15.0 10036585 - Pregnancy, puerperium and perinatal conditions 10029772 Normal pregnancy, labour and delivery HLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002982-33 Sponsor Protocol Number: 2020-PDNO-002 Start Date*: 2021-03-02
    Sponsor Name:Attgeno AB
    Full Title: An open-label, multicenter study to evaluate the efficacy, safety and tolerability of PDNO (nitrosooxypropanol) infusion in COVID-19 patients with acute pulmonary hypertension
    Medical condition: Acute pulmonary hypertension during COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004613-24 Sponsor Protocol Number: 01 Start Date*: 2016-05-30
    Sponsor Name:Radboudumc
    Full Title: Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized double-blind placebo-controlled trial.
    Medical condition: (very early) systemic sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004540-29 Sponsor Protocol Number: Pona-CELL Start Date*: 2020-10-06
    Sponsor Name:Ústav hematologie a krevní transfuze
    Full Title: Ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph-positive acute lymphoblastic leukemia
    Medical condition: NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-004551-30 Sponsor Protocol Number: ICORG08-02Nilotinib Start Date*: 2008-10-31
    Sponsor Name:ICORG
    Full Title: A phase II multi-center, open-label, study of Nilotinib at a dose of 300mg twice daily in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in ...
    Medical condition: Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 15:36:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA